Your Messages Inbox
Your Article Summary
See Latest ArticlesNovartis drug Tasigna meets primary endpoint in pivotal trial against Glivec as first-line treatment in chronic myeloid leukemia patients
Novartis, 10/21/09
Novartis announced that Tasigna met its primary endpoint in the first head–to–head comparison with the company's groundbreaking drug Glivec. Tasigna produced faster and deeper responses than Glivec when given as first–line therapy for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor